Pulmonary Disease Clinical Trial
Official title:
A Single-center Study to Assess Peak Inspiratory Flow (PIF) in Different Stages' COPD Patients by Using the In-check Method.
Peak Inspiratory Flow Rate (PIFR) is defined by the fastest flow rate noted during the
inspiratory cycle.
Inhaled medication plays an important role in the treatment of chronic obstructive pulmonary
disease (COPD), with dry powder inhalers (DPIs) increasingly replacing metered dose inhalers
(MDIs). DPIs are interesting as they do not require the need for coordinate actuation of the
MDI device with inhalation or the use of a large spacer device 1-3. Several DPIs are
available for the administration of inhaled corticosteroids, as well as bronchodilators,
with each of them corresponding to a different type of inhaler (e.g. Diskus®, Turbuhaler®,
Aeroliser®, etc.). During the inspiratory effort the patient generates a pressure drop with
a consequent airflow across the DPI. This inspiratory flow has to be high enough to
disaggregate and adequately disperse the drug powder into an aerosol cloud of drug particles
and to guarantee an optimal deposition of the medication in the lung. Such peak inspiratory
flows (PIFs) are not only dependent on a patient's inhalation effort but also on the
internal resistance of the device.
It has been shown that optimal deposition of medication with DPIs is not achieved in some
patients with low inspiratory flow rates, such as children or patients with COPD, especially
during acute exacerbations. In such conditions the use of a DPI with low internal resistance
has been suggested, ensuring an optimal deposition despite the lower flow rate. In addition,
many clinicians are nowadays confronted with an important number of COPD patients who are
aged >70 yrs
This study will assess the inspiratory flow rates at high levels of resistance in different
stages of COPD patients. PIF will be measured by in-check method.
Commonly used for Asthma patients, the In-Check Oral Inspiratory Flow Meter is a portable
hand-held inspiratory flow meter that provides an assessment of the speed of inhalation. The
In-Check Oral measures inspiratory flow between 30 and 370 L/min, inspiratory flow is
thought of by physicians as a sensitive marker for Chronic Obstructive Pulmonary Disease
(COPD) screening. The In-Check Oral works when a patient inhales through the mouth, this
will cause air to be drawn through the meter and a cursor moves along the scale to indicate
the speed of inhalation. The flow rate achieved can be noted by checking the position of the
cursor against the calibrated scale. The Standard In-Check Oral inspiratory flow meter can
measure inspiratory flow rates in the range 30 to 370 l/min, with an accuracy of +/- 10% or
10 l/min (whichever is the greater). (A Low Range In-Check Oral Inspiratory flow meter is
available by special request, measuring between 15 and 120 l/min).
All In-Check Oral meters are calibrated using an ATS pulmonary waveform generator, and the
product complies with the Australian and New Zealand standards for back pressure in flow
meters. As with any inhalation device checking for loose foreign objects is important. The
transparent body of the In-Check Oral meter is designed to allow a visual inspection before
use. The meter is manufactured from medical grade components, and is suitable for multiple
patient uses when cleaned appropriately between patients. The expected life of the In-Check
Oral, in normal use, is two years.
Commonly used for Asthma patients, the In-Check Oral Inspiratory Flow Meter is a portable
hand-held inspiratory flow meter that provides an assessment of the speed of inhalation. The
In-Check Oral measures inspiratory flow between 30 and 370 L/min, inspiratory flow is
thought of by physicians as a sensitive marker for Chronic Obstructive Pulmonary Disease
(COPD) screening. The In-Check Oral works when a patient inhales through the mouth, this
will cause air to be drawn through the meter and a cursor moves along the scale to indicate
the speed of inhalation. The flow rate achieved can be noted by checking the position of the
cursor against the calibrated scale. The Standard In-Check Oral inspiratory flow meter can
measure inspiratory flow rates in the range 30 to 370 l/min, with an accuracy of +/- 10% or
10 l/min (whichever is the greater). (A Low Range In-Check Oral Inspiratory flow meter is
available by special request, measuring between 15 and 120 l/min).
All In-Check Oral meters are calibrated using an ATS pulmonary waveform generator, and the
product complies with the Australian and New Zealand standards for back pressure in flow
meters. As with any inhalation device checking for loose foreign objects is important. The
transparent body of the In-Check Oral meter is designed to allow a visual inspection before
use. The meter is manufactured from medical grade components, and is suitable for multiple
patient use when cleaned appropriately between patients. The expected life of the In-Check
Oral, in normal use, is two years.
Commonly used for Asthma patients, the In-Check Oral Inspiratory Flow Meter is a portable
hand-held inspiratory flow meter that provides an assessment of the speed of inhalation. The
In-Check Oral measures inspiratory flow between 30 and 370 L/min, inspiratory flow is
thought of by physicians as a sensitive marker for Chronic Obstructive Pulmonary Disease
(COPD) screening. The In-Check Oral works when a patient inhales through the mouth, this
will cause air to be drawn through the meter and a cursor moves along the scale to indicate
the speed of inhalation. The flow rate achieved can be noted by checking the position of the
cursor against the calibrated scale. The Standard In-Check Oral inspiratory flow meter can
measure inspiratory flow rates in the range 30 to 370 l/min, with an accuracy of +/- 10% or
10 l/min (whichever is the greater). (A Low Range In-Check Oral Inspiratory flow meter is
available by special request, measuring between 15 and 120 l/min).
- All In-Check Oral meters are calibrated using an ATS pulmonary waveform generator, and
the product complies with the Australian and New Zealand standards for back pressure in
flow meters. As with any inhalation device checking for loose foreign objects is
important. The transparent body of the In-Check Oral meter is designed to allow a
visual inspection before use. The meter is manufactured from medical grade components,
and is suitable for multiple patient use when cleaned appropriately between patients.
The expected life of the In-Check Oral, in normal use, is two Accurately measures oral
inspiratory flow rate (peak and sub-maximal) in order to assess suitability for inhaled
medication
- Measures nasal inspiratory flow for assessing nasal airway patency
- Assesses response to nasal provocation
- Allows home monitoring of Peak Nasal Inspiratory Flow (PNIF)
- Easy to use, clean and reset, the In-Check helps patients maintain their respiratory
health.
- High-quality medical-grade stainless steel and plastic construction
- Sterilizable plastic mouthpiece accepts different mask sizes
- Simple enough for home patient use, rugged enough for routine clinic use.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02504697 -
DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
|
||
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Terminated |
NCT00524095 -
Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis
|
Phase 2 | |
Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
Completed |
NCT00023114 -
p450 Mediated Lung Toxicity
|
N/A | |
Recruiting |
NCT06056882 -
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
|
||
Completed |
NCT03994848 -
Incentive Spirometry Prehabilitation Study
|
N/A | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Withdrawn |
NCT05100160 -
Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)
|
Phase 3 | |
Completed |
NCT03229473 -
Fall Risk Assessment in COPD
|
||
Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04996693 -
On Dose Efficiency of Modern CT-scanners in Chest Scans
|
N/A | |
Recruiting |
NCT04996173 -
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
|
N/A | |
Completed |
NCT04601545 -
The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method
|
N/A | |
Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
Recruiting |
NCT02862418 -
Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)
|